Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT)

About LABT

Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

5

Website

lakewoodamedex.com

Fundamentals

1-day range

$2.22$2.44

Market cap

$5.28M

P/E (trailing)

—

P/E (forward)

—

EPS (trailing)

$-3.26

Dividend yield

—

Beta

-1.38

Avg. volume

1.48M

Lakewood-Amedex Biotherapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• LABT

  Lakewood-Amedex Biotherapeutics Inc. Common Stock

  $2.3

  ▼ 4.56%
  Market cap $5.28MP/E —
  $0.366$9.82
• GOVX

  GeoVax Labs Inc. Common Stock

  $0.7195

  ▲ 0.35%
  Market cap $5.34MP/E —
  $0.59$19.2
• BGMS

  Bio Green Med Solution Inc. Common Stock

  $0.86

  ▼ 3.37%
  Market cap $5.35MP/E 0.18
  $0.5664$8.82
• NCNA

  NuCana plc American Depositary Share

  $1.79

  ▲ 21.43%
  Market cap $5.62MP/E 0.01
  $1.21$7.22
• APVO

  Aptevo Therapeutics Inc. Common Stock

  $2.36

  ▼ 2.48%
  Market cap $4.92MP/E 0.00
  $2.3$48.78
• JUNS

  Jupiter Neurosciences Inc. Common Stock

  $4.59

  ▼ 6.13%
  Market cap $5.65MP/E —
  $4.1$138
• HCWB

  HCW Biologics Inc. Common Stock

  $3.39

  ▲ 6.94%
  Market cap $6.06MP/E —
  $1.5$38.16

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Watching Lakewood-Amedex Biotherapeutics; Zacks Small-Cap Research Gives Stock $12 Price Valuation
  benzinga · 8/26/2026

• Tucker Joseph Edward · April 24, 2026 · Grant

  33.8K